Moreover, elevated FRAS1/FREM expression levels were significantly correlated with cancer progression (pathological stage, pathological grade and tumor metastasis status), poor survival (OS, DSS and PFS), immune infiltrations (MMR, TMB, MSI and CD4+ T cells subsets) and DNA methylation in KIRC patients, sharing the potential as efficient markers of the prognostic value of KIRC and potential targets in the development of anti-KIRC therapeutics. Here, FRAS1 is linked to neoplasm.